Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Jinying Tian"'
Autor:
Yunfei Song, Jianbo Yang, Wenguang Jing, Qi Wang, Yue Liu, Xianlong Cheng, Fei Ye, Jinying Tian, Feng Wei, Shuangcheng Ma
Publikováno v:
Chinese Medicine, Vol 15, Iss 1, Pp 1-15 (2020)
Abstract Background Diabetes is a complex metabolic disease characterized by hyperglycemia, plaguing the whole world. However, the action mode of multi-component and multi-target for traditional Chinese medicine (TCM) could be a promising treatment o
Externí odkaz:
https://doaj.org/article/07c1b8a2aeb94e2caff7784aeec666a5
Autor:
Jiang Li, Xiaolin Zhang, Jinying Tian, Juan Li, Xuechen Li, Song Wu, Yuying Liu, Jingyan Han, Fei Ye
Publikováno v:
Pharmaceuticals, Vol 16, Iss 1, p 106 (2023)
Nonalcoholic fatty liver disease (NAFLD) is one of the common metabolic diseases characterized by hepatic lipid accumulation. Insulin resistance and microcirculation dysfunction are strongly associated with NAFLD. CX08005, an inhibitor of PTP1B with
Externí odkaz:
https://doaj.org/article/12735e52cdf3442180cff7015566befc
Autor:
Xuechen Li, Zhenxin Yan, Mattias Carlström, Jinying Tian, Xiaolin Zhang, Wenxuan Zhang, Song Wu, Fei Ye
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
Hyperuricemia is characterized by abnormally high level of circulating uric acid in the blood and is associated with increased risk of kidney injury. The pathophysiological mechanisms leading to hyperuricemic nephropathy (HN) involve oxidative stress
Externí odkaz:
https://doaj.org/article/bd3a88e2e5a744f5a68f0644d888a464
Autor:
Yanbo Tang, Xiaolin Zhang, Zheng Chen, Wenwen Yin, Guanglei Nan, Jinying Tian, Fei Ye, Zhiyan Xiao
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 8, Iss 6, Pp 919-932 (2018)
Based on a non-competitive and selective PTP1B inhibitor reported by us previously, thirty-nine benzamido derivatives were designed and synthesized as novel PTP1B inhibitors. Among them, twelve compounds exhibited IC50 values at micromolar level agai
Externí odkaz:
https://doaj.org/article/3d73d60b78ae43f991287f28a6609c32
Autor:
Qin Yi, Puyang Sun, Juan Li, Siming Kong, Jinying Tian, Xuechen Li, Yanan Yang, Peicheng Zhang, Yuying Liu, Jingyan Han, Xiaolin Zhang, Fei Ye
Publikováno v:
Frontiers in Physiology, Vol 9 (2018)
The prevalence of non-alcoholic fatty liver disease (NAFLD), which is developed from hepatic steatosis, is increasing worldwide. However, no specific drugs for NAFLD have been approved yet. To observe the effects of Rho, a fraction from Rhodiola cren
Externí odkaz:
https://doaj.org/article/1f6ba4dc357f4c7eb737cd9a0afa9a34
Autor:
Chuangjun Li, Li Li, Chao Wang, Jingzhi Yang, Fei Ye, Jinying Tian, Yikang Si, Dongming Zhang
Publikováno v:
Molecules, Vol 17, Iss 12, Pp 13960-13968 (2012)
A new ursane-type nortriterpenoid, (11S,12S)-4-methyl-11,12-epoxy-2-hydroxy-3-oxoursa-1,4-dine-28-oic acid γ-lactone (1), named ulmoidol A, together with ten known compounds: ulmoidol (2), corosolic acid (3), 2α,3α-dihydroxy-24-nor-4(23),12-oleana
Externí odkaz:
https://doaj.org/article/518025be26404cc69c71a88e72069122
Autor:
Mohan Sun, Xianjie Ma, Siyuan Shao, Jianwei Jiang, Jiaan Li, Jinying Tian, Jianjun Zhang, Li Li, Fei Ye, Shuai Li
Publikováno v:
Organic & Biomolecular Chemistry. 20:4736-4745
Two pairs of novel trimeric dihydrophenanthrene–bibenzyl–dihydrophenanthrene enantiomers, together with three rare polymers were isolated from Bletilla striata. Some compounds showed significant anti-inflammatory and PTP1B inhibitory activities.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f34d927b27e5cda848ead43a93ba20cb
https://doi.org/10.1039/d2ob00489e
https://doi.org/10.1039/d2ob00489e
Autor:
Shihao Cheng, Qinglin Wang, Xi Chen, Jiahao Chen, Bin Wang, Dongni Chen, Dong Shen, Jinying Tian, Fei Ye, Yu Lu, Haihong Huang, Yongjun Lu, Dongfeng Zhang
Publikováno v:
Bioorganicmedicinal chemistry. 73
Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) is an important virulence factor that blocks the host immune response and facilitates M. tuberculosis growth in host cells. MptpB inhibitors are potential components of tuberculosis co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a0f8f61d0dfcecc19deef72582a41ce
https://pubmed.ncbi.nlm.nih.gov/36150342
https://pubmed.ncbi.nlm.nih.gov/36150342
Autor:
Yajun Yang, Dingan Yan, Hanzeng Cheng, Guanglei Nan, Xianxin Hou, Long Ren, Ying Yang, Xuechen Li, Jinying Tian, Fei Ye, Zhiyan Xiao
Publikováno v:
Bioorganic chemistry. 129
Xanthine oxidoreductase (XOR) is a clinically validated target for the treatment of hyperuricemia and gout. A series of novel 1,2,4-triazoles were identified as potent XO inhibitors via a fused-pharmacophore strategy based on the interaction modes of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a7610bd675d1a2b8d9498624663531d
https://pubmed.ncbi.nlm.nih.gov/36183564
https://pubmed.ncbi.nlm.nih.gov/36183564
Autor:
Zhiyan Xiao, Yajun Yang, Dingan Yan, Hanzeng Cheng, Guanglei Nan, Xianxin Hou, Long Ren, Ying Yang, Xuechen Li, Jinying Tian, Fei Ye
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a471a410929f6f2b763a175b7b4ce86
https://doi.org/10.2139/ssrn.4043820
https://doi.org/10.2139/ssrn.4043820